Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the potential of the AR-V7 test

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelinesПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPCПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, on the evolving treatment landscape of nmCRPCПодробнее

Nicholas Vogelzang, MD, FASCO, FACP | Perspective on Cancer Care in the Time of COVID-19Подробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patientsПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial testПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancerПодробнее

Nicholas J. Vogelzang, MD, regarding the latest trends in diagnosis of advanced prostate cancerПодробнее

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancerПодробнее

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancerПодробнее

Dr. Vogelzang Discusses PROSPECT Trial for Prostate CancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on identifying the best patients for Zytiga versus XtandiПодробнее

Nicholas Vogelzang, MD, explains how cabazitaxel should be used in various lines of treatment in mPCПодробнее

Prostate Cancer: Educating Physicians About AR-V7 TestingПодробнее

Dr. Nicholas Vogelzang Discusses Latest Advances in Prostate CancerПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPCПодробнее

Nicholas Vogelzang, MD, FASCO, FACP | Addressing Patients on Cancer Care in the Time of COVID-19Подробнее